Precision and personalized medicine in the pharmaceutical industry advance through groundbreaking patents, fueling innovation in targeted therapies. Leading companies underscore this progress with strategic deals and investments, emphasizing the industry’s commitment to advancement. Simultaneously, a surge in job opportunities reflects the sector’s dynamic growth in the pursuit of personalized healthcare solutions.GlobalData’s precision and personalized medicine market report covers the key trends, opportunity forecasts, impactful case studies, and a thematic scorecard ranking companies based on their investment in top industry themes. Buy the report here.
This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding precision and personalized medicine. It provides an overview of recent developments in precision and personalized medicine-related deals, talent acquisition, and patent filings within the pharmaceutical industry.
Diverse applications of precision and personalized medicine in pharmaceutical industry
Pharmaceutical companies specializing in precision and personalized medicine are leveraging groundbreaking patents to propel targeted therapies forward. The patent "Inhibitors of LINE1 and uses thereof" is a notable example, focusing on suppressing LINE1 expression to potentially revolutionize precision medicine by specifically targeting genetic elements. Another significant patent, "Methods of genome editing including controlled opening of chromatin," introduces an ex vivo method for site-specific genome editing. This employs histone deacetylase inhibitors and a Cas9 ribonucleoprotein to facilitate precise modifications to an individual's genetic makeup, further advancing the field.
In cancer research, the patent "Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma" not only provides diagnostic assays but also includes targeted therapies. This allows the development of personalized treatment plans based on specific mutations, showcasing the industry's commitment to tailoring treatments. Additionally, patents such as "Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins" address diseases linked to abnormal protein levels, reflecting a dedicated focus on developing targeted therapies for conditions arising from protein dysregulation.
A comprehensive approach is exemplified by the patent "Derived multiple allogeneic proteins paracrine signaling (d-MAPPS) regenerative biologics platform technology adjuvant therapy for the prevention and targeted treatment of cancer and other disorders." This outlines a regenerative biologics platform for cancer treatment, utilizing mesenchymal stem cells and growth factors from placental tissue to suppress cancer cell growth, and its integration with other active agents enhances its therapeutic potential.
Overall, these patents highlight the advancements in precision and personalized medicine technologies and applications. By leveraging these technologies, pharmaceutical companies can develop targeted therapies, improve diagnostic methods, and enhance treatment outcomes for various diseases and disorders. The acquirer of these patents stands to benefit from the potential commercialization of these innovations, leading to improved precision and personalized medicine options for patients.
The industry experienced a 44% decline in the number of precision and personalized medicine-related patent applications in Q3 2023 compared with the previous quarter. On an annual basis, the number of precision and personalized medicine-related patent applications in the pharmaceutical industry witnessed a drop of 84% compared with Q3 2022.
Strategic deal trends in precision and personalized medicine in pharmaceutical industry
Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in precision and personalized medicine. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of precision and personalized medicine in the pharmaceutical industry.
In Q3 2023, the number of precision and personalized medicine-related deals in the pharmaceutical industry declined by 33% compared with Q3 2022. On a quarterly basis, there was 59% drop in the number of deals in Q3 2023 compared with the previous quarter.
Impact on hiring
In terms of new job posting, in Q3 2023, the pharmaceutical industry experienced a 6% growth compared with the previous quarter. On an annual basis, job postings also grew by 45%. Notably, management occupations, with a share of 24%, emerged as the top precision and personalized medicine-related job roles within the pharmaceutical industry in Q3 2023, with new job postings rising by 20% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 22% in Q3 2023, with new job postings dropping by 8% over the previous quarter. The other prominent precision and personalized medicine roles include healthcare practitioners and technical occupations with a 7% share in Q3 2023, and computer and mathematical occupations with a 4% share of new job postings.
AbbVie, AstraZeneca, Ionis Pharmaceuticals, Sarepta Therapeutics, and F. Hoffmann-La Roche are among the top companies leading in precision and personalized medicine hiring within the pharmaceutical industry.
Countries driving adoption of precision and personalized medicine in pharmaceutical industry
The US is the leading country in precision and personalized medicine adoption within the pharmaceutical industry, boasting the highest number of precision and personalized medicine-related patents, jobs, and deals. Meanwhile, Australia, the UK, China and Canada also maintain significant positions in precision and personalized medicine adoption within the pharmaceutical industry.
In conclusion, the pharmaceutical industry's pivot towards precision and personalized medicine is evident through strategic deals, innovative patents, and a notable surge in job opportunities. As companies navigate this transformative landscape, the integration of groundbreaking technologies promises enhanced treatment outcomes and underscores the global significance of precision medicine adoption.
To further understand GlobalData's analysis on precision and personalized medicine in the pharmaceutical industry, buy the report here.